Replimune Group Stock Technical Analysis
| REPL Stock | USD 7.03 0.36 4.87% |
As of the 2nd of February, Replimune holds the Coefficient Of Variation of (987.11), variance of 12.96, and Risk Adjusted Performance of (0.07). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Replimune, as well as the relationship between them. Please check Replimune Group market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Replimune Group is priced some-what accurately, providing market reflects its current price of 7.03 per share. Given that Replimune has information ratio of (0.11), we recommend you to check out Replimune Group's recent market performance to make sure the company can sustain itself at a future point.
Replimune Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Replimune, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to ReplimuneReplimune | Build AI portfolio with Replimune Stock |
Replimune Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 12.57 | Strong Buy | 8 | Odds |
Most Replimune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Replimune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Replimune Group, talking to its executives and customers, or listening to Replimune conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Replimune 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Replimune's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Replimune.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Replimune on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Replimune Group or generate 0.0% return on investment in Replimune over 90 days. Replimune is related to or competes with Ginkgo Bioworks, MBX Biosciences, Iovance Biotherapeutics, ArriVent BioPharma, MeiraGTx Holdings, Prime Medicine, and Valneva SE. Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer More
Replimune Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Replimune's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Replimune Group upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 20.44 | |||
| Value At Risk | (5.32) | |||
| Potential Upside | 5.56 |
Replimune Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Replimune's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Replimune's standard deviation. In reality, there are many statistical measures that can use Replimune historical prices to predict the future Replimune's volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.48) |
Replimune February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.47) | |||
| Mean Deviation | 2.7 | |||
| Coefficient Of Variation | (987.11) | |||
| Standard Deviation | 3.6 | |||
| Variance | 12.96 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.48) | |||
| Maximum Drawdown | 20.44 | |||
| Value At Risk | (5.32) | |||
| Potential Upside | 5.56 | |||
| Skewness | 0.636 | |||
| Kurtosis | 1.55 |
Replimune Group Backtested Returns
Replimune Group maintains Sharpe Ratio (i.e., Efficiency) of -0.11, which implies the firm had a -0.11 % return per unit of risk over the last 3 months. Replimune Group exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Replimune's Variance of 12.96, risk adjusted performance of (0.07), and Coefficient Of Variation of (987.11) to confirm the risk estimate we provide. The company holds a Beta of 0.78, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Replimune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Replimune is expected to be smaller as well. At this point, Replimune Group has a negative expected return of -0.35%. Please make sure to check Replimune's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Replimune Group performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.81 |
Excellent reverse predictability
Replimune Group has excellent reverse predictability. Overlapping area represents the amount of predictability between Replimune time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Replimune Group price movement. The serial correlation of -0.81 indicates that around 81.0% of current Replimune price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.81 | |
| Spearman Rank Test | -0.87 | |
| Residual Average | 0.0 | |
| Price Variance | 1.13 |
Replimune technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Replimune Group Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Replimune Group volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Replimune Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Replimune Group on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Replimune Group based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Replimune Group price pattern first instead of the macroeconomic environment surrounding Replimune Group. By analyzing Replimune's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Replimune's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Replimune specific price patterns or momentum indicators. Please read more on our technical analysis page.
Replimune February 2, 2026 Technical Indicators
Most technical analysis of Replimune help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Replimune from various momentum indicators to cycle indicators. When you analyze Replimune charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.47) | |||
| Mean Deviation | 2.7 | |||
| Coefficient Of Variation | (987.11) | |||
| Standard Deviation | 3.6 | |||
| Variance | 12.96 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.48) | |||
| Maximum Drawdown | 20.44 | |||
| Value At Risk | (5.32) | |||
| Potential Upside | 5.56 | |||
| Skewness | 0.636 | |||
| Kurtosis | 1.55 |
Replimune February 2, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Replimune stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.06 | ||
| Daily Balance Of Power | (0.84) | ||
| Rate Of Daily Change | 0.95 | ||
| Day Median Price | 7.20 | ||
| Day Typical Price | 7.14 | ||
| Price Action Indicator | (0.34) | ||
| Market Facilitation Index | 0.43 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.